Envisia Therapeutics Announces Positive Three-Month Interim Results of Low Dose ENV515 in Patients with Glaucoma

News | 05. 04. 2016

Envisia Therapeutics

RESEARCH TRIANGLE PARK, N.C., May 3, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported positive results from an interim three-month analysis of an ongoing 12-month safety and efficacy evaluation of the low dosage form of ENV515 XR (travoprost). ENV515, the Company’s lead product candidate, is an extended-release formulation of travoprost that could offer sustained reduction in intraocular pressure (IOP) for more than six months after a single dose.